Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Open Access
- 12 October 2024
- journal article
- research article
- Published by Springer Nature in Apoptosis
- Vol. 29 (11-12) , 2047-2073
Abstract
Triple-negative breast cancer (TNBC) presents a significant challenge for treatment due to its aggressive nature and the lack of effective therapies. This study developed dual inhibitors against cell division cycle 25 (CDC25) and histone deacetylases (HDACs) for TNBC treatment. CDC25 phosphatases are crucial for activating cyclin-dependent kinases (CDKs), the master regulators of cell cycle progression. HDACs regulate various biological processes by deacetylating histone and non-histone proteins, affecting gene expression, chromatin structure, cell differentiation, and proliferation. Dysregulations of HDAC and CDC25 are associated with several human malignancies. We generated a group of dual inhibitors for CDC25 and HDAC by combining the molecular structures of CDC25 (quinoline-5,8-dione) and HDAC (hydroxamic acid or benzamide) pharmacophores. The newly developed compounds were evaluated against various solid-tumor, leukemia, and non-malignant breast epithelial cells. Among the synthesized compounds, 18A emerged as a potent inhibitor, demonstrating significant cytotoxicity against TNBC cells, superior to its effects on other cancer types while sparing non-malignant cells. 18A possessed similar HDAC inhibitory activity as MS-275 and potently suppressed CDC25 activity in vitro and the CDK1 dephosphorylation in cells. Additionally, 18A hindered the progression of S and G2/M phases, triggered DNA damage, and induced apoptosis. These findings underscore the potential of 18A as a targeted therapy for TNBC and warrants further preclinical development. Graphical AbstractKeywords
All Related Versions
Funding Information
- National Science and Technology Council of Taiwan (111-2113-M-038-004, 112-2113-M-038-001, 112-2320-B-038-004)
- Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (DP2-TMU-113-C-03)
This publication has 44 references indexed in Scilit:
- Heterocycles–Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen YearsChemMedChem, 2024
- Hdac1-deficiency affects the cell cycle axis Cdc25-Cdk1 causing impaired G2/M phase progression and reduced cardiomyocyte proliferation in zebrafishBiochemical and Biophysical Research Communications, 2023
- Targeting histone deacetylases for cancer therapy: Trends and challengesActa Pharmaceutica Sinica B, 2023
- Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implicationsMedical Oncology, 2022
- Cancer statistics for the year 2020: An overviewInternational Journal of Cancer, 2021
- Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2Bioorganic & Medicinal Chemistry Letters, 2019
- Epigenetic polypharmacology: A new frontier for epi‐drug discoveryMedicinal Research Reviews, 2019
- Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25BBioorganic & Medicinal Chemistry, 2015
- Novel anti-inflammatory function of NSC95397 by the suppression of multiple kinasesBiochemical Pharmacology, 2014
- A novel coumarin‐quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell deathMolecular Carcinogenesis, 2013